Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fruquintinib - HUTCHMED

Next Previous
X
Search
Drug Profile

Fruquintinib - HUTCHMED

Alternative Names: Aiyoute; Elunate; FRUZAQLA; HMPL-013; TAK-113

Latest Information Update: 06 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer BeiGene; Eli Lilly and Company; Genor Biopharma; Hutchison MediPharma; HUTCHMED; Shanghai Junshi Biosciences
  • Class Antineoplastics; Benzofurans; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Registered Endometrial cancer
  • Phase III Non-small cell lung cancer
  • Phase II/III Renal cell carcinoma
  • Phase II Solid tumours
  • Phase I/II Triple negative breast cancer
  • Preregistration Submission Withdrawal Gastric cancer

Most Recent Events

  • 03 Dec 2024 Registered for Endometrial cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Metastatic disease) in China (PO)
  • 21 Nov 2024 Launched for Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Recurrent) in Japan (PO)
  • 31 Oct 2024 Registered for Colorectal cancer in Argentina (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top